TheEdgeResearch
Home / Stocks / VILGF

Yourgene Health Plc (VILGF)

OTC Healthcare Medical - Diagnostics & Research
$0.00 ▲ +0.00%
Market Cap
$20.7M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.86
52-Wk Range
5.0E-4-0.138
CEO
Lyn Dafydd Rees
Country
GB
Currency
USD

Yourgene Health Plc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Manchester, GB. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $20.7M. On trailing twelve-month figures it carries a trailing P/E of -1.97, a net margin of -5.1%. Its beta of 0.86 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.97
Price / Sales
0.44
Price / Book
0.11
EV / EBITDA
14.28
Gross margin
56.9%
Operating margin
-6.8%
Net margin
-5.1%
Return on equity
Debt / equity
0.58
Current ratio
1.77
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
253
IPO date
2013-03-28
Headquarters
Manchester, GB
About Yourgene Health Plc

Yourgene Health Plc is a molecular diagnostics firm specializing in the development, manufacturing, and commercialization of advanced genomic solutions, primarily for prenatal screening and diverse other applications across the UK, Europe, and globally. The company's in-vitro diagnostic (IVD) portfolio features key products such as the IONA Test, a non-invasive prenatal test (NIPT) for screening pregnant women for Down's, Edwards', and Patau's syndromes. Other diagnostics include Cystic Fibrosis Screening tests, Rapid Aneuploidy Analysis (a confirmatory diagnostic performed post-amniocentesis), and a Recurrent Pregnancy Loss PCR assay that identifies the six most common chromosomes linked to miscarriage. Additionally, it offers DPYD genotyping products. Beyond these, Yourgene Health provides Ranger, a technology platform facilitating sample size selection and enrichment. It also offers the Elucigene DPYD assay, a PCR test crucial for predicting patient response to chemotherapy, and the Clarigene SARS-CoV-2 CE-IVD, a PCR assay utilized for standard COVID-19 testing. The company further extends its offerings to clinical research organizations (CROs) through a comprehensive suite of genomic services. These include sample preparation and analysis tools, bioinformatics and software solutions, along with specialized services such as DNA, RNA/miRNA, and nucleonic extraction, quantification, genotyping, gene expression analysis, methylation studies, and microarray services. Established in 2000, the company, formerly known as Premaitha Health PLC until its rebranding in November 2018, is headquartered in Manchester, United Kingdom.

Comparable companies

Yourgene Health Plc is most often compared with the following Healthcare names:

ATHJFBFFTFGRAMFHDSLFKMSTFOCELPCHMRTNXFVNNYFVRCDF
More research on VILGF
VILGF technical analysis VILGF TheEdge Score Compare against peers
Open full interactive analysis & DCF →